Trial Profile

Combination of CM082 With JS001 in Patients With Advanced Non-Small Cell Lung Cancer (SCLC) Who Progressed on First-line Treatment: a Phase II Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; Vorolanib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors AnewPharma

Most Recent Events

08 Jun 2021 Results (n=18) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
07 Jul 2020 Planned End Date changed from 1 Feb 2021 to 1 Sep 2021.
07 Jul 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com